US OptionsDetailed Quotes
NUVB241220C2500
- 0.15
- 0.000.00%
15min DelayClose Dec 20 16:00 ET
0.00High0.00Low
0.00Open0.15Pre Close0 Volume21 Open Interest2.50Strike Price0.00Turnover0.00%IV-6.69%PremiumDec 20, 2024Expiry Date0.34Intrinsic Value100Multiplier-17DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma18.93Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Nuvation Bio Stock Discussion
$Nuvation Bio (NUVB.US)$
U.S. Food and Drug Administration Accepts for Priority Review Nuvation Bio’s New Drug Application for Taletrectinib for the Treatment of Advanced Ros1-Positive Non-Small Cell Lung Cancer! June 23, 2025
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
Nuvation Bio (NYSE: NUVB) announced positive pooled data from TRUST-I and TRUST-II studies evaluating taletrectinib, a next-generation ROS1 TKI for advanced ROS1-positive NSCLC. Key findings include:
- 89% tumor shr...
Tumors shrank in 91% of taletrectinib-treated patients with advanced ROS1-positive NSCLC who were ROS1 TKI-naïve and 52% of those who were ROS1 TKI-pretreated in the study
Responses were durable with long-term follow-up; 71% of TKI-naïve patients were still progression-free at two years
TRUST-I is one of t...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
NEWS
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
Nuvation Bio completes the acquisition of AnHeart Therapeutics, transforming into a late-stage global oncology company. Shareholders now own approximately 67% and 33% of NUVB, setting the stage for potential commercial success by 2025.
⇒ $137.5M deal at $20.42/sh 💰💰
⇒ strengthens portfolio in inflammatory & autoimmune diseases
⇒ Adds lead asset NX-13 (Ph2 trial UC)
$Nuvation Bio (NUVB.US)$ to acquire AnHeart Therapeutics
⇒ all-stock transaction
⇒ transforms NUVB into late-stage global oncology company
⇒ Includes taletrectinib with ongoing trials NSCLC)
$Novo-Nordisk A/S (NVO.US)$ to acquire Cardior Pharmaceuticals
⇒ 1.025 B euros deal 💰💰
⇒ strengthens pi...
No comment yet